
Annovis Bio (ANVS) Stock Forecast & Price Target
Annovis Bio (ANVS) Analyst Ratings
Bulls say
Annovis Bio is an attractive investment opportunity due to the potential success of their lead candidate, buntanetap, in treating Alzheimer's disease, Parkinson's disease, and Lewy body dementia. Positive results from ongoing clinical trials, such as the reduction of sAPP in early Alzheimer's patients and the ongoing enrollment in the Phase 3 open-label extension study for Parkinson's disease, provide strong support for the company's promising mechanism of action and potential market opportunity. This, combined with the recent raise securing their funding needs and a potential 1Q27 trial readout, make ANVS significantly undervalued with the potential for high returns in the future.
Bears say
Annovis Bio is facing challenges in gaining approval for their flagship drug buntanetap, as the likelihood of approval is estimated at 25%. The company's expected peak sales in 2037 are moderately low at $2.5 billion, indicating that their product may have limited market potential. In addition, their reliance on future raises and regulatory milestones for financial success may pose a risk to investors.
This aggregate rating is based on analysts' research of Annovis Bio and is not a guaranteed prediction by Public.com or investment advice.
Annovis Bio (ANVS) Analyst Forecast & Price Prediction
Start investing in Annovis Bio (ANVS)
Order type
Buy in
Order amount
Est. shares
0 shares